Atossa Genetics Inc. WT EXP 052421

ATOWW - US OTC
Save to watchlist

Add to calculator

Compare stock
Overview
Stock analysis
Dividends
Fundamentals
Atossa Genetics Inc. WT EXP 052421
ATOWW
-
US OTC
Overview
Stock analysis
Dividends
Fundamentals

Overview

About stock

Other
Sector
Other
Industry

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons.

Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.

Similar stocks

Report issue